Compare WINA & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WINA | INVA |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1993 | 2004 |
| Metric | WINA | INVA |
|---|---|---|
| Price | $404.96 | $19.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $36.80 |
| AVG Volume (30 Days) | 82.0K | ★ 969.9K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | 2.56 | ★ 53.96 |
| EPS | ★ 11.21 | 1.52 |
| Revenue | $84,517,400.00 | ★ $388,521,000.00 |
| Revenue This Year | $7.05 | $13.23 |
| Revenue Next Year | $3.60 | $8.58 |
| P/E Ratio | $36.11 | ★ $13.05 |
| Revenue Growth | 3.35 | ★ 10.14 |
| 52 Week Low | $295.79 | $16.52 |
| 52 Week High | $527.37 | $22.76 |
| Indicator | WINA | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 41.39 | 45.64 |
| Support Level | $398.07 | $19.52 |
| Resistance Level | $420.04 | $20.27 |
| Average True Range (ATR) | 15.41 | 0.49 |
| MACD | -2.09 | -0.07 |
| Stochastic Oscillator | 12.06 | 40.58 |
Winmark Corp is a franchisor of value-oriented retail store concepts that buy, sell, and trade gently used merchandise. The company has one reportable segment including Franchising and one non-reportable segment Leasing. The franchising segment franchises value-oriented retail store that buys, sell, trade, and consign merchandise as well as provide strategic consulting services relating to franchising. The leasing segment includes middle-market equipment leasing business and small-ticket financing business. It generates a majority of its revenue from the Franchising segment.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.